What is Exact Sciences Corporation (EXAS)?

Exact Sciences Corporation (EXAS) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of EXAS?

The current price of EXAS is $104.91. Prices are updated in real time on Stocks360.

What is EXAS's price-to-earnings (PE) ratio?

EXAS's trailing twelve-month PE ratio is -188.59, based on current price and earnings per share data available on Stocks360.

What is EXAS's market capitalization?

EXAS's market capitalization is $20,026,082,216.00, placing it in the large-cap tier.

Exact Sciences Corporation (EXAS)

Stock analysis · NASDAQ · Healthcare · Medical - Diagnostics & Research

$104.91

Market Cap

$20.03B

PE (TTM)

-188.59

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.44

Day Range

$104.91 – $104.91

52-wk Range

$38.81 – $104.98

Avg Volume

N/A

Volume

21.56M

Exact Sciences Corporation (EXAS) is a publicly traded company in the Healthcare sector. Latest price: $104.91. Market cap $20.03B. Trailing PE -188.59. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $62.74 2026-03-23 · $104.91 (+67.21%)

Earnings

Most Recent

Feb 13, 2026

EPS $-0.45 vs est. $-0.11

Missed by $0.34

Proprietary Signals

Signal snapshot temporarily unavailable.

About Exact Sciences Corporation

Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains imp…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-188.59×
P/S (TTM)	7.88×
P/B	8.29×
P/FCF (TTM)	56.07×
EV / EBITDA	233.57×
EV / Sales	8.50×
Earnings Yield	-0.54%
Free Cash Flow Yield	1.78%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$21.59B
Revenue (TTM)	$2.54B
Net Income (TTM)	-$107.38M
Free Cash Flow (TTM)	$386.01M
Net Debt	$1.57B
Working Capital	$788.41M
Gross Margin	69.37%
Operating Margin	-4.11%
Net Margin	-4.20%
Return on Equity	-4.34%
Return on Invested Capital	-2.11%